Drug intelligence / Profile preview

RotaTeq + placebo

Development stage: Unknown
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Oral

Overview

RotaTeq is a live, oral pentavalent vaccine developed by Merck Sharp & Dohme LLC, containing five live reassortant rotaviruses (strains G1, G2, G3, G4, and P1). It is primarily indicated for the prevention of rotavirus gastroenteritis in infants aged 6 to 32 weeks. The specific designation "RotaTeq + placebo" refers to a regimen evaluated in a Phase I clinical trial (V260-027) involving elderly subjects (65-80 years), where participants received a combination of the active vaccine and placebo doses to assess safety and immunogenicity. This trial was terminated after Part I due to business decisions, representing an off-label investigation of the vaccine in a non-standard population.

Other names: RotaTeq + placebo

Targets

RVA (Rotavirus A)

Beyond the preview

Go deeper on RotaTeq + placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RotaTeq + placebo.

Explore the full profile